SSRIs, particularly sertraline, are the most widely recommended antidepressants for people with heart disease. The American Heart Association identifies SSRIs as the first-line pharmacotherapy for depression in patients with coronary artery disease, based on their favorable cardiovascular safety profile compared to older antidepressant classes. But “safe” isn’t one-size-fits-all: the best choice depends on your specific heart condition, the medications you already take, and individual risk factors like age and sex.
Why SSRIs Are the First Choice
SSRIs work by increasing serotonin levels in the brain without significantly affecting the electrical conduction system of the heart. Among them, sertraline has the strongest safety evidence in cardiac patients. In clinical trials involving people recovering from heart attacks or unstable angina, sertraline improved mood and was well tolerated by more than 85% of participants. Patients taking sertraline also had fewer cardiac events (death, heart attack, stroke, worsening angina, or new heart failure) compared to those on placebo, though the study wasn’t large enough to confirm that as a definitive benefit.
Not all SSRIs carry the same cardiac risk, though. Citalopram causes dose-dependent prolongation of the QT interval, a measure of the heart’s electrical recovery time between beats. When the QT interval stretches too long, it raises the risk of a dangerous rhythm called Torsades de Pointes, which can cause sudden cardiac arrest. The FDA capped citalopram’s maximum dose at 40 mg per day for the general population and 20 mg per day for people over 60, those with liver problems, or those taking certain other medications. The FDA specifically discourages citalopram in people with congenital long QT syndrome, slow heart rate, low potassium or magnesium levels, recent heart attack, or uncompensated heart failure. Escitalopram, a closely related drug, also appears on lists of antidepressants with possible QT-prolonging risk.
Antidepressants Heart Patients Should Avoid
Tricyclic antidepressants (TCAs) like amitriptyline, nortriptyline, and imipramine carry the most concerning cardiovascular profile. Even at standard therapeutic doses, TCAs increase heart rate, cause drops in blood pressure when standing, and disrupt the heart’s electrical conduction. The most common rhythm disturbance they trigger is an abnormally fast resting heart rate, driven by their effects on the nervous system. More seriously, they can cause heart block (where electrical signals between the upper and lower chambers slow or stop) and dangerous ventricular arrhythmias. In overdose, these conduction problems can be fatal. For these reasons, both TCAs and monoamine oxidase inhibitors (MAOIs) are considered to have unfavorable cardiovascular safety profiles and are generally avoided in heart patients.
Trazodone and nefazodone, sometimes prescribed as sleep aids or antidepressants, should also be avoided due to their own QT-prolonging effects and risk of ventricular arrhythmias.
SNRIs: A Middle Ground With Caveats
SNRIs like venlafaxine and duloxetine boost both serotonin and norepinephrine. That extra norepinephrine can stimulate the cardiovascular system, leading to mild increases in heart rate and blood pressure. For someone with well-controlled blood pressure, this may be manageable with monitoring. But for people with existing hypertension or heart failure, the American Heart Association recommends SSRIs over SNRIs specifically because of this tendency toward elevated blood pressure and faster heart rate.
Venlafaxine in particular requires blood pressure monitoring throughout treatment. At therapeutic doses, neither venlafaxine nor duloxetine has been linked to QT abnormalities, but venlafaxine can prolong the QT interval at toxic doses or in patients with additional risk factors. It is listed among antidepressants that may warrant ECG monitoring in vulnerable patients.
Bupropion’s Cardiac Profile
Bupropion works differently from SSRIs and SNRIs, primarily affecting dopamine and norepinephrine. In a study of depressed patients who already had impaired heart function, ventricular arrhythmias, or conduction disease, bupropion did not worsen arrhythmias, did not cause significant conduction problems, had a low rate of blood pressure drops on standing, and did not change heart rate. These features make its cardiovascular profile relatively favorable. However, it did raise blood pressure in the lying-down position, and about 14% of study participants had to stop taking it due to side effects, including worsening of pre-existing high blood pressure in two patients. If your primary cardiac concern is arrhythmia or conduction disease rather than hypertension, bupropion may be a reasonable option.
Special Concerns for Heart Failure
Depression is common in heart failure, but treating it with antidepressants in this population has proven frustratingly difficult. A major German trial (MOOD-HF) tested escitalopram in 372 patients with chronic heart failure and reduced pumping ability alongside depression. After a median of about 18 months, escitalopram performed no better than placebo for preventing death or hospitalization, and it didn’t significantly improve depression scores either. Safety was comparable between the two groups, meaning escitalopram didn’t cause harm, but it didn’t help either.
Based on findings like these, current recommendations suggest that people with heart failure may benefit more from non-drug approaches. Cognitive behavioral therapy and structured exercise programs are considered preferable first-line treatments for depression in heart failure, since the usefulness of SSRIs in this specific group remains uncertain.
Bleeding Risk With Blood Thinners
Many heart patients take aspirin or other blood-thinning medications daily, and this creates an important interaction with SSRIs. Serotonin plays a role in blood clotting, and by reducing serotonin activity in platelets, SSRIs independently increase bleeding risk. When combined with aspirin, the risk of gastrointestinal bleeding rises by about 27%. The risk varies by specific SSRI: paroxetine combined with aspirin showed the highest bleeding risk, with a 73% increase compared to aspirin alone. SSRIs have also been linked to increased bleeding in surgical settings and heavier menstrual periods.
This doesn’t necessarily mean you can’t take an SSRI while on aspirin, but it’s a factor that influences which antidepressant and what dose makes sense for your situation. SNRIs carry a similar bleeding concern. Your prescriber may also consider whether a stomach-protecting medication is appropriate alongside the combination.
When an ECG Is Needed First
Not every heart patient needs an electrocardiogram before starting an antidepressant, but many do. ECG screening before and after starting treatment is recommended when the antidepressant being considered has known QT-prolonging potential (citalopram, escitalopram, venlafaxine, and mirtazapine are among those flagged) and the patient has vulnerability to QT prolongation. That vulnerability includes:
- Known risk factors: a previously prolonged QT interval, personal or family history of dangerous heart rhythms, or family history of sudden cardiac death
- Two or more general risk factors: age over 65, female sex, taking another QT-prolonging medication, existing heart disease (prior heart attack, heart failure, valve disease, cardiomyopathy), doses above the recommended range, or low calcium, potassium, or magnesium levels
When ECG monitoring is warranted, the standard approach is to get a baseline reading before starting the medication and a follow-up about one week after reaching the target dose, once the drug has reached steady levels in the body. If the QT interval is found to be persistently above 500 milliseconds, the medication should be stopped. If none of these risk factors apply, a pre-treatment ECG generally isn’t necessary.
Choosing the Right Fit
The decision comes down to your specific cardiac diagnosis. For coronary artery disease or a history of heart attack, sertraline has the strongest safety data. For heart failure, non-drug therapies like cognitive behavioral therapy and exercise may be more effective than medication. If blood pressure is your primary concern, SSRIs are preferred over SNRIs. If you take aspirin or other antiplatelet drugs, the added bleeding risk of SSRIs needs to be weighed against their mood benefits. And if arrhythmia is the worry, avoiding citalopram at higher doses, TCAs, and trazodone is essential.
Newer antidepressants continue to show promise. Vortioxetine, a multimodal antidepressant, was tested at both standard and supratherapeutic doses in a rigorous cardiac safety trial and showed no meaningful effect on heart rhythm at either dose level. Options like these expand the toolkit for cardiac patients who need depression treatment without added heart risk.